A detailed history of Lgt Group Foundation transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Lgt Group Foundation holds 21,729 shares of GILD stock, worth $2.01 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
21,729
Previous 25,694 15.43%
Holding current value
$2.01 Million
Previous $1.76 Million 3.35%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $264,029 - $333,020
-3,965 Reduced 15.43%
21,729 $1.82 Million
Q2 2024

Aug 07, 2024

SELL
$63.15 - $72.88 $107,986 - $124,624
-1,710 Reduced 6.24%
25,694 $1.76 Million
Q1 2024

May 14, 2024

SELL
$71.58 - $87.29 $153,038 - $186,626
-2,138 Reduced 7.24%
27,404 $2.01 Million
Q4 2023

Feb 06, 2024

SELL
$73.27 - $83.09 $169,986 - $192,768
-2,320 Reduced 7.28%
29,542 $2.39 Million
Q3 2023

Nov 06, 2023

BUY
$73.94 - $80.67 $105,734 - $115,358
1,430 Added 4.7%
31,862 $2.39 Million
Q2 2023

Jul 27, 2023

SELL
$76.01 - $86.7 $290,586 - $331,454
-3,823 Reduced 11.16%
30,432 $2.35 Million
Q1 2023

Apr 20, 2023

SELL
$77.31 - $88.08 $3.69 Million - $4.2 Million
-47,668 Reduced 58.19%
34,255 $2.84 Million
Q4 2022

Feb 09, 2023

SELL
$62.32 - $89.47 $2.02 Million - $2.9 Million
-32,412 Reduced 28.35%
81,923 $7.03 Million
Q3 2022

Oct 19, 2022

BUY
$59.54 - $68.01 $16,611 - $18,974
279 Added 0.24%
114,335 $7.05 Million
Q2 2022

Aug 03, 2022

BUY
$57.72 - $65.01 $379,162 - $427,050
6,569 Added 6.11%
114,056 $7.05 Million
Q1 2022

May 11, 2022

BUY
$57.92 - $72.58 $2.25 Million - $2.82 Million
38,810 Added 56.51%
107,487 $6.41 Million
Q4 2021

May 03, 2022

BUY
$64.88 - $73.64 $4.46 Million - $5.06 Million
68,677 New
68,677 $4.99 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $116B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Lgt Group Foundation Portfolio

Follow Lgt Group Foundation and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lgt Group Foundation, based on Form 13F filings with the SEC.

News

Stay updated on Lgt Group Foundation with notifications on news.